Stock of the week: “Guardant Health, Inc.”

Guardant Health, Inc. is our “stock of the week”. Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. In short, the company is screening for cancer using a simple blood test. It's the kind of innovation that Guardant officials say will unlock a potential $80 billion market.

• Financial social media sentiment is “positive” in both absolute and relative terms – on its own and when compared to the sentiment of the sector and the sentiment of the stock index.

• Analysts' consensus rating is "buy" - out of the 18 bank analysts covering the company, 16 recommend buying the stock, and 2 suggest holding. The upside potential of the stock price expected by the analysts on average over the next 6-12 months is currently 95.24% (reference close of business 31/10/2022).

• Attention buzz is currently “Average”.

Sources:  

https://www.forbes.com/sites/jonmarkman/2022/10/17/blood-test-for-cancer-gives-new-life-to-guardant-health-shares/

https://umushroom.com/en/equity/guardant-health-rg